Literature DB >> 8239593

Antileishmanial activity of sodium stibogluconate fractions.

W L Roberts1, P M Rainey.   

Abstract

Sodium stibogluconate, a pentavalent antimony derivative produced by the reaction of stibonic and gluconic acids, is the drug of choice for the treatment of leishmaniasis. It has been reported to be a complex mixture rather than a single compound. We separated sodium stibogluconate into 12 fractions by anion-exchange chromatography. One fraction accounted for virtually all the leishmanicidal activity of the fractionated material against Leishmania panamensis promastigotes, with a 50% inhibitory concentration (IC50) of 12 micrograms of Sb per ml; that of unfractionated sodium stibogluconate was 154 micrograms of Sb per ml. Further analysis of this active fraction revealed that a major component was m-chlorocresol, which had been included in the sodium stibogluconate formulation as a preservative. The IC50 of pure m-chlorocresol was 1.6 micrograms/ml, a concentration equivalent to that present in unfractionated sodium stibogluconate at a concentration of 160 micrograms of Sb per ml. After ether extraction to remove m-chlorocresol, the IC50 of sodium stibogluconate was > 4,000 micrograms of Sb per ml. In contrast, when L. panamensis amastigotes were grown in macrophages, the IC50 of ether-extracted sodium stibogluconate was 10.3 micrograms of Sb per ml. The 12 fractions of ether-extracted sodium stibogluconate obtained by anion-exchange chromatography had IC50s of 10.1 to 15.4 micrograms of Sb per ml. We conclude that preservative-free sodium stibogluconate has little activity against L. panamensis promastigotes but is highly active against L. panamensis amastigotes in macrophages. This activity is associated with multiple chemical species.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239593      PMCID: PMC188079          DOI: 10.1128/AAC.37.9.1842

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  EXPERIMENTS ON THE MECHANISM OF ACTION OF CHLOROCRESOL AND CAFFEINE.

Authors:  D F BIGGS
Journal:  Br J Pharmacol Chemother       Date:  1965-04

2.  Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.

Authors:  R Badaro; E Falcoff; F S Badaro; E M Carvalho; D Pedral-Sampaio; A Barral; J S Carvalho; M Barral-Netto; M Brandely; L Silva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

3.  Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.

Authors:  J D Chulay; L Fleckenstein; D H Smith
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

4.  Semiautomated assessment of in vitro activity of potential antileishmanial drugs.

Authors:  J D Berman; J V Gallalee
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  The leishmaniases.

Authors:  E A Steck
Journal:  Prog Drug Res       Date:  1974

6.  Human cutaneous lieshmania in a mouse macrophage line: propagation and isolation of intracellular parasites.

Authors:  K P Chang
Journal:  Science       Date:  1980-09-12       Impact factor: 47.728

7.  Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy.

Authors:  J E Jackson; J D Tally; W Y Ellis; Y B Mebrahtu; P G Lawyer; J B Were; S G Reed; D M Panisko; B L Limmer
Journal:  Am J Trop Med Hyg       Date:  1990-11       Impact factor: 2.345

8.  Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam).

Authors:  J D Berman; M Grogl
Journal:  Exp Parasitol       Date:  1988-10       Impact factor: 2.011

9.  Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy.

Authors:  W L Roberts; P M Rainey
Journal:  Anal Biochem       Date:  1993-05-15       Impact factor: 3.365

10.  Biochemical and molecular characterization of Leishmania pifanoi amastigotes in continuous axenic culture.

Authors:  P M Rainey; T W Spithill; D McMahon-Pratt; A A Pan
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

  10 in total
  24 in total

1.  Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.

Authors:  Helen Denton; Joanne C McGregor; Graham H Coombs
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

Review 2.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime).

Authors:  W L Roberts; W J McMurray; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes.

Authors:  M Ephros; E Waldman; D Zilberstein
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis.

Authors:  Abdurrahim Kocyigit; Selahaddin Gur; Mehmet S Gurel; Vedat Bulut; Mustafa Ulukanligil
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening.

Authors:  D Sereno; G Roy; J L Lemesre; B Papadopoulou; M Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes.

Authors:  A Lucumi; S Robledo; V Gama; N G Saravia
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.

Authors:  W L Roberts; J D Berman; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.